Globus Medical Director Stephen T. Zarrilli Executes Stock Options and Sells Shares on August 18, 2026
Globus Medical Director Stephen T. Zarrilli exercised stock options for 25,000 shares of Class A Common Stock on August 18, 2026, at $53.27 per share. On the same day, he sold all 25,000 shares at a weighted average price of $87.0386 per share, resulting in zero direct beneficial ownership of Globus Medical stock after the transactions. The options were granted in January 2020 and were fully vested.
Globus Medical (NYSE: GMED) director exercises options, sells 25,000 shares
Globus Medical (NYSE: GMED) director Stephen T. Zarrilli exercised 25,000 stock options at $53.27 per share and subsequently sold all 25,000 shares of Class A Common Stock at a weighted average price of $87.0386 per share. This transaction resulted in approximately $844,000 pre-tax spread for the director. The options were fully vested and granted on January 22, 2020.
Is Revenue Growth Amid Margin Pressure Altering The Investment Case For Globus Medical (GMED)?
Globus Medical (GMED) reported second-quarter 2026 results with increased sales but a decline in net income and EPS, reaffirming its full-year revenue outlook. The company's investment case hinges on translating revenue growth into durable profits amidst integration and cost control challenges from acquisitions. While revenue guidance remains firm, investors are urged to consider margin pressure and acquisition risks that could affect future profitability.
Is Globus Medical (GMED) Cheap After Its Earnings Beat And Higher EPS Outlook?
Globus Medical (GMED) has seen positive momentum with a 7.39% 90-day share price return following an earnings beat and higher EPS outlook. Despite a year-to-date dip, its 1-year total shareholder return is 40.41%. A valuation narrative suggests the stock is 23.3% undervalued, with a fair value of $107.42, driven by integration synergies and expected margin expansion from recent acquisitions.
Globus Medical (GMED) Stock Leans On Margin Gains As Nevro Recovery Lags
Globus Medical (GMED) reported a strong Q2 2026 with record non-GAAP earnings per share and a high adjusted EBITDA margin, indicating significant margin strength. Despite these gains, the company faces challenges with Nevro sales declining and robotics adoption being slower than anticipated, leading to some unmet operational milestones. The article suggests that while margin expansion is doing heavy lifting, investors should assess the company's cash generation and debt profile.
Is Rising Revenue But Weaker Margins Altering The Investment Case For Globus Medical (GMED)?
Globus Medical (GMED) recently reported Q2 2026 results showing increased revenue but decreased net income and diluted EPS, indicating margin compression. While the company reaffirmed its full-year revenue outlook, the focus has shifted to cost control and integration of acquisitions to improve profitability. The article suggests investors should consider both optimistic and cautious analyst views on future performance given the current margin pressures.
Globus Medical (NYSE: GMED) lifts 2026 EPS outlook on strong Q2 performance
Globus Medical (NYSE: GMED) announced strong second-quarter 2026 results, with worldwide net sales increasing by 5.9% to $789.6 million and non-GAAP diluted EPS rising 55.8% to $1.34. The company reaffirmed its 2026 revenue guidance of $3.18–$3.22 billion but raised its non-GAAP fully diluted EPS outlook to $4.95–$5.05, up from the previous range of $4.70–$4.80. This positive revision reflects improved profitability and disciplined execution, despite a GAAP EPS decline primarily due to a prior-year bargain purchase gain related to the Nevro acquisition.
Is Globus Medical (GMED) Undervalued Or Is Its Recent Rebound Already Priced In?
Globus Medical (GMED) stock has seen renewed attention following a 7.84% gain over the last seven days, despite declines over the past 30 and 90 days. While the company's 1-year total shareholder return is positive at 52.33%, investors are debating whether the recent rebound indicates an undervalued stock or if the re-rating is complete. Simply Wall St's analysis suggests Globus Medical is undervalued with a fair value of $107.42, citing innovation in robotics and minimally invasive procedures, but also notes execution risks.
Globus Medical (GMED) Stock Could Be Undervalued Following Q2 Earnings Date
Globus Medical (GMED) stock has seen a significant return of 49.1% over the past year, yet current valuations suggest it may still be undervalued, particularly when considering its P/E ratio compared to the Medical Equipment industry and its peers. The company's tailored fair P/E multiple is estimated at 26.4x, higher than its current 18.6x, indicating a potential discount. The upcoming Q2 earnings release in early August will be crucial in shaping investor views on its growth prospects and whether the market will fully price in its fundamentals.
Globus Medical (GMED) director reports bona fide gift of 2,500 shares
Globus Medical director David D. Davidar reported a bona fide gift of 2,500 Class A Common Stock shares on July 27, 2026. This transaction was not part of a Rule 10b5-1 trading plan. Following the gift, Davidar directly holds 507,675 shares and indirectly owns 165,967 shares through the Davidar Family Irrevocable Trust for the benefit of his spouse and children.
Globus Medical Director David Davidar Transfers 2,500 Shares in Non-Sale Transaction
Globus Medical Director David Davidar transferred 2,500 shares of Class A Common Stock on July 27, 2026, as disclosed in a regulatory filing. This non-sale transaction reduced his direct beneficial ownership while his indirect holdings through a family trust remained significant. The disclosure offers insights into insider trading at the orthopedic implant and surgical robotics manufacturer.
Kuehn Law Encourages Investors of Globus Medical, Inc. to Contact Law Firm
Kuehn Law, PLLC is investigating whether officers and directors of Globus Medical, Inc. (NYSE: GMED) breached their fiduciary duties to shareholders through potential self-dealing. The firm is encouraging long-term GMED stockholders to contact them to explore potential damages and corporate governance reforms, emphasizing that participation can contribute to market integrity. The consultation and case are free, with all costs covered by Kuehn Law.
Globus Medical Inc Class A Revenue Breakdown – DUS:GM0N
This article provides a revenue breakdown for Globus Medical Inc Class A (DUS:GM0N), highlighting its top-performing segment, Musculoskeletal Solutions, which generated €2.38 billion last year. The United States was the largest contributor to revenue, accounting for €2.02 billion. The company's total revenue for the last year was €2.50 billion.
Globus Medical Inc Class A Revenue Breakdown – TRADEGATE:GM0N
Globus Medical Inc Class A generated €2.50 billion in revenue last year, with its Musculoskeletal Solutions segment contributing the most at €2.38 billion. The majority of this revenue, €2.02 billion, came from the United States. This indicates a strong focus and performance in musculoskeletal solutions within the U.S. market.
ETFs Investing in Globus Medical Inc Class A Stocks
This article provides a comprehensive list of Exchange Traded Funds (ETFs) that hold Globus Medical Inc Class A stocks. The ETFs are sorted by market value and include details such as issuer, management style, focus, expense ratio, assets under management (AUM), price, change percentage, relative volume, and 3-year NAV total return. The information helps investors identify various funds that offer exposure to Globus Medical, Inc.
What Globus Medical (GMED)'s Robotics-Focused Institutional Interest Means For Shareholders
Globus Medical (GMED) has seen increased institutional interest due to its focus on robotics, navigation, and minimally invasive procedures, particularly its ExcelsiusGPS ecosystem. This renewed attention reinforces the company's investment narrative centered on durable growth from these technologies, with reaffirmed 2026 revenue guidance of US$3.18 billion to US$3.22 billion. The article suggests investors should consider whether its robotic platforms can translate this into high-margin recurring revenue, while also being aware of potential cost pressures and aggressive growth assumptions.
Globus Medical (GMED) Secures FDA Clearances As Revenue And R And D Stay Strong
Globus Medical (GMED) has secured new FDA clearances, expanding its product offerings in spine and orthopedic surgery. This development, coupled with strong revenue growth and a steady commitment to R&D, positions the company as an innovative and high-growth investment, especially when compared to competitors like Medtronic. An analysis by Simply Wall St suggests GMED shares are currently undervalued, trading significantly below analyst targets and their estimated fair value.
Globus Medical Inc Class A Actuals & Estimates (GETTEX:GM0N)
This article provides actuals and estimates for Globus Medical Inc Class A (GM0N) traded on GETTEX, including its current stock price, historical performance, analyst forecasts, and financial data. It covers revenue, earnings per share, net income, market capitalization, and volatility, along with information on upcoming earnings reports.
Globus Medical Inc Class A Actuals & Estimates (HAM:GM0N)
This article provides actuals and estimates for Globus Medical Inc Class A (HAM:GM0N), covering financial data from income statements, balance sheets, and cash flow statements, alongside analyst forecasts. It details the company's stock performance, market capitalization, earnings, revenue, and EBITDA. The report also addresses frequently asked questions regarding its stock price, ticker, volatility, and dividend policy.
Price to sales forward of Globus Medical Inc Class A – TRADEGATE:GM0N
This article provides the "Price to sales forward" for Globus Medical Inc Class A (GM0N) on the Tradegate Exchange. It highlights the current value, change, and percentage change for this financial metric. The information is presented within the context of TradingView's financial data offerings.
How Globus Medical Inc. Class A (GMED) Affects Rotational Strategy Timing
This article analyzes Globus Medical Inc. Class A (GMED) using AI models to provide trading strategies for different risk profiles. It highlights a strong near-term sentiment shifting to a long-term positive bias, with an impressive 53.9:1 risk-reward setup. The analysis offers specific entry, target, and stop-loss points for position trading, momentum breakout, and risk hedging strategies.
Globus Medical Inc Class A Actuals & Estimates (FWB:GM0N)
This article provides an overview of Globus Medical Inc Class A (FWB:GM0N) stock, including its current price, market capitalization, historical performance, and analyst forecasts. It details financial actuals and estimates such as earnings per share and revenue for recent quarters, and mentions that the company does not pay dividends. Investors are advised to conduct comprehensive research before investing, considering the company’s financials, news, and technical analysis.
GM0N Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for Globus Medical Inc Class A (GM0N) stock. It includes analyst ratings, earnings estimates, revenue expectations, and historical price performance, highlighting that analysts project a maximum price of 105.48 EUR and a minimum of 75.22 EUR. The company's current stock price is 72.28 EUR, and it is expected to release its next earnings report on July 30, 2026.
GM0N Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for Globus Medical Inc Class A (GM0N) stock, detailing analyst opinions with a maximum estimate of 105.48 EUR and a minimum of 75.22 EUR. It covers current stock performance, historical highs and lows, volatility, market capitalization, and upcoming earnings reports, offering a comprehensive overview for potential investors. The article also includes various financial metrics and answers frequently asked questions about the company.
Globus Medical Inc Class A Actuals & Estimates (NYSE:GMED)
This article provides an overview of Globus Medical, Inc. (NYSE:GMED) stock, including its current price, performance trends, analyst forecasts, and financial data. It highlights the company's financial results, market capitalization, and upcoming earnings report, while emphasizing that the information is not investment advice.
Globus Medical Inc Class A Actuals & Estimates (BX:GMED)
This article provides an overview of Globus Medical Inc Class A (GMED) stock, including its financial actuals and estimates. It details analyst price targets, past earnings and revenue, future earnings report dates, and key financial metrics like EBITDA. The article also provides information on how to buy GMED stock and answers frequently asked questions about the company's financials and employee count.
How Globus Medical Inc. Class A (GMED) Affects Rotational Strategy Timing
This article analyzes Globus Medical Inc. Class A (GMED) from a rotational strategy perspective, highlighting a strong near-term sentiment shifting towards mid-term neutrality and long-term positive bias. It details institutional trading strategies, including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis and AI-generated signals for support and resistance levels. The report suggests an exceptional risk-reward setup for GMED.
Globus Medical updates guidance after NuVasive merger close, shares react on NASDAQ
Globus Medical has issued updated post-merger guidance following its all-stock acquisition of NuVasive, detailing revenue synergies, margin expectations, and integration costs for investors. The combined entity is poised to compete more directly with larger spine and orthopedics peers, benefiting from a diversified product mix. Analysts emphasize that successful integration and synergy realization will be crucial for future margin progression.
GM0N Forecast — Price Target — Prediction for 2027
This article provides a forecast for Globus Medical Inc Class A (GM0N) stock, including analyst price targets and ratings. It details the stock's current performance, historical highs and lows, volatility, market capitalization, and upcoming earnings report. The piece also answers frequently asked questions regarding GM0N's financial health and investment outlook.
GMED Forecast — Price Target — Prediction for 2027
This article provides a forecast for Globus Medical Inc Class A (GMED) stock, including analyst price targets, historical and estimated EPS and revenue, and other financial metrics. It details the stock's current price, volatility, market capitalization, upcoming earnings reports, and EBITDA. The information is presented by TradingView and includes answers to frequently asked questions about GMED.
GMED Forecast — Price Target — Prediction for 2027
This article provides a forecast for Globus Medical Inc Class A (GMED) stock, including analyst price targets, current stock performance, and financial data. It highlights the stock's recent price movements, earnings reports, revenue figures, and market capitalization, along with a disclaimer that the information is not investment advice.
Globus Medical Inc Class A Actuals & Estimates (BMV:GMED)
This article provides an overview of Globus Medical Inc Class A (GMED) stock performance, financial estimates, and analyst forecasts on the Mexican Stock Exchange. It details current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings dates. The content also addresses frequently asked questions regarding GMED's financials and investment outlook.
Price to earnings forward of Globus Medical Inc Class A – BIVA:GMED
This page displays the "Price to earnings forward" metric for Globus Medical Inc Class A (GMED) on the BIVA exchange. It indicates that the market was closed at the time of viewing, with no trades reported. The content also notes the data source and copyright information.
Globus Medical Director Sold Shares Worth Over $2M
A director at Globus Medical, David D. Davidar, sold Class A Common Stock totaling over $2 million on June 5, 2026. The shares were sold at a weighted average price of $80.7629. Following this transaction, Davidar David D. directly owns 510,175 Class A Common Stock and indirectly holds 165,967 shares in a family trust.
Globus Medical Inc Class A Actuals & Estimates (BOATS:GMED)
This article provides an overview of Globus Medical, Inc. (GMED) stock, focusing on its financial actuals and analyst estimates. It details the company's past earnings and revenue, future projections, stock price history, and key financial metrics like EBITDA. The article also confirms that GMED does not pay dividends and will release its next earnings report on July 30, 2026.
Earnings Beat Amid Currency Headwinds Might Change The Case For Investing In Globus Medical (GMED)
Globus Medical (GMED) reported better-than-expected Q1 2026 financial results, which positively influenced investor sentiment despite ongoing inflation, interest rate uncertainty, and foreign currency pressures. The company reaffirmed its full-year 2026 revenue guidance of US$3.18–3.22 billion, indicating management's effort to balance strong performance with continued external challenges. While the earnings beat supports short-term profit, investors are advised to remain vigilant regarding foreign currency and international integration risks, which could still impact long-term value.
Globus Medical (GMED) Stock Could Be 28% Undervalued Despite Recent Share Price Bounce
Globus Medical (GMED) stock has seen a recent bounce but is still down over the past month and three months. Despite a nearly 37% total shareholder return over the last year, the stock is currently perceived by some analyses as 28% undervalued, with a fair value anchored at $110 per share. This valuation hinges on the success of its robotics and digital surgery ecosystem, as well as the integration of NuVasive and Nevro.
(GMED) and the Role of Price-Sensitive Allocations
This article analyzes Globus Medical Inc. Class A (NASDAQ: GMED), noting divergent sentiment and potential for lower levels. It details AI-generated trading strategies including position, momentum, and risk hedging, along with multi-timeframe signal analysis for support and resistance levels. The report highlights elevated downside risk and advises on accessing real-time signals and institutional-grade analysis.
Globus Medical (GMED) Stock After 36% One-Year Gain Is There Still Upside?
Globus Medical (GMED) has seen a 36% gain over the past year, prompting an analysis of its current valuation. According to Simply Wall St's discounted cash flow (DCF) model and P/E ratio analysis, the stock appears to be significantly undervalued by approximately 49.6%. The article also introduces narratives as a way for investors to customize their valuation perspective based on factors like robotics shift, international expansion, and acquisitions.
What Globus Medical (GMED)'s Upgraded Earnings Outlook and Rising ROIC Concerns Mean For Shareholders
Globus Medical reported a strong Q1 2026 with 27% revenue growth and increased its non-GAAP EPS outlook, driven by strength in spine and enabling technologies and the Nevro acquisition integration. Despite this positive earnings momentum, the company faces rising concerns regarding its declining return on invested capital (ROIC), which questions its efficiency in sustaining profitable growth amid global expansion and new product rollouts. The article discusses how these upgraded earnings and ROIC concerns reshape Globus Medical's investment narrative, with analysts offering differing views on its future performance and fair value.
Madison Small Cap Fund Sold Globus Medical (GMED) as Valuation Exceeded
Madison Small Cap Fund liquidated its position in Globus Medical (GMED) after the company successfully integrated its Nuvasive acquisition and saw its market capitalization reach $12 billion, which exceeded the fund's intrinsic value estimate of $85 per share against a market price of $90. The fund aims to focus on smaller alternatives, despite GMED's strong revenue growth and increased hedge fund interest. Madison Small Cap Fund also notes that it believes certain AI stocks offer greater upside potential with less downside risk.
Total assets of Globus Medical Inc Class A – XETR:GM0N
The article displays the "Total assets" section for Globus Medical Inc Class A (XETR:GM0N) on TradingView. It provides a table structure with columns for "Period," "Value," "Change," and "Change %" but no specific data is populated. This page is part of the financial overview for the company on the platform.
Preferred dividends of Globus Medical Inc Class A – XETR:GM0N
This page provides information on the preferred dividends of Globus Medical Inc Class A, traded on the XETR exchange under the symbol GM0N. It is part of TradingView's financial data section, offering an overview of market data, financials, news, community insights, and forecasts for the company. The specific dividend values and changes for different periods are available on this dedicated page.
Globus Medical (NYSE: GMED) director exercises options, sells 25,000 shares
Globus Medical director David D. Davidar engaged in an exercise-and-sell transaction, exercising stock options for 25,000 shares at $26.27 each and simultaneously selling those 25,000 shares in the open market for a weighted average price of $80.7629. Following these transactions, Davidar directly holds 510,175 shares, with an additional 165,967 shares held indirectly through a family irrevocable trust. This activity is detailed in a recent Form 4 filing, outlining the specific prices and holdings.
Globus Medical (GMED) director exercises options for 25,000 new shares
Globus Medical director Ann D. Rhoads exercised stock options to acquire 25,000 shares of Class A Common Stock at $26.27 per share. These options, granted on January 30, 2017, were fully vested. Following this transaction, Ms. Rhoads now directly owns 40,384 shares of GMED, with no related share sales reported in this filing.
Tangible book value per share of Globus Medical Inc Class A – XETR:GM0N
This article provides financial information for Globus Medical Inc Class A (XETR:GM0N), specifically focusing on its tangible book value per share. The content is presented within the TradingView platform, which offers various market data and analysis tools for investors.
Pretax income of Globus Medical Inc Class A – XETR:GM0N
The article provides financial information for Globus Medical Inc Class A (XETR:GM0N), specifically focusing on its pretax income. It indicates that the market for this stock is currently closed. The data is sourced from ICE Data Services and FactSet, with SEC filings by Quartr.
Is Globus Medical’s (GMED) Robotics Leasing Shift Quietly Reshaping Its Earnings Quality?
Globus Medical (GMED) recently reported strong first-quarter results with 27% revenue growth, driven by its core spine business and expansion of its Enabling Technologies customer base. The company is shifting its Excelsius robotic platform to leasing and rental models, tied to implants and services, which could increase recurring revenue. This strategic move, along with FDA clearances, aims to enhance earnings quality, though investors should consider integration and competition risks.
Operating expenses (excl. COGS) of Globus Medical Inc Class A – XETR:GM0N
This article displays the operating expenses (excluding Cost of Goods Sold) for Globus Medical Inc Class A, traded on XETR under the symbol GM0N. It presents a data table with "Period," "Value," "Change," and "Change %" columns for these expenses. The page is part of a larger financial data platform, TradingView, providing financial information for GM0N.
Globus Medical Inc Class A Trade Ideas — XETR:GM0N
This article compiles various trade ideas and analyses for Globus Medical Inc Class A (GM0N/GMED) from different traders on TradingView. The analyses range from bullish outlooks based on strong earnings, technical breakouts, and long-term investment potential, to observations of short-term weakness and resistance levels. Several contributors highlight recent strong Q1 2026 earnings, share buyback programs, and technical patterns like bull flags, symmetrical triangles, and channel support as key factors influencing their trade strategies.
